Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 21,197 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunity Disorders Clear all
Terminated Phase 3 Interventional

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

NCT01002248
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Perifosine, Perifosine Placebo, Bortezomib, Dexamethasone
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
39
States / cities
La Verne, California • San Francisco, California • San Pablo, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2018 · Synced Oct 20, 2026, 1:39 PM EDT
Terminated Phase 4 Interventional Results available

Kaletra and Viread in Antiretroviral Naïve Patients

NCT00679926
View directory record Official record
Conditions
HIV Infections
Interventions
Once daily
Drug
Lead sponsor
Oklahoma State University Center for Health Sciences
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 20, 2026, 1:39 PM EDT
Completed Phase 2 Interventional Results available

Short Course Daratumumab in Patients With Multiple Myeloma

NCT03490344
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Lenalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 20, 2026, 1:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Wheat Bioactives and Immune Function

NCT02210234
View directory record Official record
Conditions
Endocrine, Nutritional, Metabolic and Immunity Disorders
Interventions
50 grams of whole wheat bran cereal, 100 grams of whole wheat bran cereal
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 20, 2026, 1:39 PM EDT
Completed Phase 3 Interventional Results available

Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes

NCT04233034
View directory record Official record
Conditions
Type1 Diabetes
Interventions
HCL, verapamil 120mg tablet, non-HCL, placebo
Device · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
7 Years to 17 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 20, 2026, 1:39 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

NCT03870763
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Dimethyl Fumarate, Peginterferon Beta-1a, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 20, 2026, 1:39 PM EDT
Completed Phase 3 Interventional Results available

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

NCT01476787
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Rituximab, Lenalidomide, Rituximab-CHOP, Rituximab-CVP, Rituximab-Bendamustine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
26
States / cities
Chandler, Arizona • Fullerton, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 20, 2026, 1:39 PM EDT
Completed Not applicable Interventional

Enhancing Treatment Adherence in Pediatric Asthma With a Problem Solving Intervention

NCT00149487
View directory record Official record
Conditions
Asthma
Interventions
Tailored Problem Solving Intervention, Family Education Intervention
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
6 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2022 · Synced Oct 20, 2026, 1:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells

NCT00630721
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
IFNbeta-1b
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 20, 2026, 1:39 PM EDT
Terminated Phase 2 Interventional Results available

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)

NCT01685021
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
MOR00208 (formerly Xmab5574)
Drug
Lead sponsor
MorphoSys AG
Industry
Eligibility
16 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Columbus, Ohio • Memphis, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 20, 2026, 1:39 PM EDT
Completed No phase listed Observational

Trauma Routing Algorithm for Pediatrics

NCT03359421
View directory record Official record
Conditions
Pediatric All, Trauma
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
2 Days to 18 Years
Enrollment
4,801 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 20, 2026, 1:39 PM EDT
Completed Phase 2 Interventional Results available

Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)

NCT01168921
View directory record Official record
Conditions
CLL, Leukemia
Interventions
Eltrombopag
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 20, 2026, 1:39 PM EDT
Completed Phase 3 Interventional Results available

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

NCT03734016
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Zanubrutinib, Ibrutinib
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
30
States / cities
Little Rock, Arkansas • Los Angeles, California • Boulder, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 20, 2026, 1:39 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant

NCT02506933
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Cytomegaloviral Infection, Hodgkin Lymphoma, Lymphadenopathy, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Interventions
Laboratory Biomarker Analysis, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Placebo
Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
3
States / cities
Duarte, California • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 20, 2026, 1:39 PM EDT
Completed Phase 2 Interventional Results available

Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation

NCT00990249
View directory record Official record
Conditions
Leukemia, Lymphoma, Allogeneic Haematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia
Interventions
Busulfan, Clofarabine, Thymoglobulin, Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 20, 2026, 1:39 PM EDT
Completed Not applicable Interventional

Efficacy of Group Intervention to Reduce Stress Symptoms

NCT00611338
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, HIV Infections
Interventions
HIV Skills-based Prevention
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 20, 2026, 1:39 PM EDT
Completed Phase 3 Interventional Results available

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

NCT02414958
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
34
States / cities
Escondido, California • Huntington Beach, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 20, 2026, 1:39 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

NCT01864148
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BIIB033, Placebo, Avonex
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
11
States / cities
Cullman, Alabama • Phoenix, Arizona • Raleigh, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 20, 2026, 1:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing Two Models of PrEP Delivery in OBGYN Clinics

NCT05015855
View directory record Official record
Conditions
Hiv
Interventions
NP-PC PrEP, OBGYN-PrEP
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 20, 2026, 1:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ACT with NMOSD Patients and Caregivers Pilot Study

NCT05840055
View directory record Official record
Conditions
NMO Spectrum Disorder
Interventions
Acceptance and Commitment Therapy
Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 20, 2026, 1:39 PM EDT
Terminated Not applicable Interventional Results available

Efficacy of Lubiprostone in Combination With Standard PEG Preparation

NCT00689026
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Lubiprostone, Polyethylene glycol with electrolytes
Drug · Other
Lead sponsor
Augusta University
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Oct 20, 2026, 1:39 PM EDT
Recruiting Early Phase 1 Interventional

Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder

NCT06934915
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism Spectrum Disorders, Autistic Disorder, Autism
Interventions
Prednisone, Placebo
Drug
Lead sponsor
Christopher John McDougle, M.D.
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 20, 2026, 1:39 PM EDT
Completed Not applicable Interventional

Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients

NCT00001131
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin, HAART
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Oct 20, 2026, 1:39 PM EDT
Completed Phase 3 Interventional

Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer

NCT00053053
View directory record Official record
Conditions
Cachexia, Lymphoma, Lymphoproliferative Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Juven, Non-Juven Supplement
Dietary Supplement
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
17 Years to 120 Years
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
230
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 181 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 20, 2026, 1:39 PM EDT